title: [The roles of platelet activating factor in intestinal mucosal barrier injury after burn].
abstract: In order to investigate the roles of platelet activating factor (PAF) in postburn intestinal barrier injury, the changes in intestinal mucosal potential difference (PD), intestinal PAF, Phospholipase A2 (PLA2), myeloperoxidase (MPO) and malondialdehyde (MDA) were measured in a model of rats with 30% TBSA III degrees burns. The results showed that the intestinal PAF level was significantly elevated after severe burn and was negatively correlated with the decrease of intestinal mucosal PD (r = -0.94, P < 0.01). PAF antagonist WEB 2170 treatment could significantly inhibite the increase of PAF in intestinal tissue, enhance intestinal mucosal PD, attenuate the levels of PLA2, MPO and MDA in intestinal tissue, and alleviate the pathological changes in ileal mucosa, compared with the burn group. The results suggest that PAF is an important factor causing postburn intestinal mucosal barrier injury, and activation of leukocyte and PLA2 as well as the release of superoxide are important intermediate mechanisms for PAF leading to intestinal mucosal injury.
authors.affiliation: Burn Research Institute, Southwest Hospital, Third Military Medical College, Chongquing.
authors.forename: P
authors.initials: P
authors.lastname: Yu
authors.forename: G
authors.initials: G
authors.lastname: Xiao
authors.forename: W
authors.initials: W
authors.lastname: Fu
mesh_terms: D000818:Animals; D001381:Azepines / Q000627:therapeutic use; D002056:Burns / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D007413:Intestinal Mucosa / Q000378:metabolism*; D008297:Male; D008564:Membrane Potentials; D009195:Peroxidase / Q000378:metabolism; D010741:Phospholipases A / Q000502:physiology; D054467:Phospholipases A2; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D001381:Azepines; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D014230:Triazoles; C063964:bepafant; D009195:Peroxidase; D010741:Phospholipases A; D054467:Phospholipases A2